NTLA Intellia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NTLA

Price (delayed)

$14.8

Market cap

$2.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.53

Enterprise value

$2.01B

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 37

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The company's debt fell by 33% YoY and by 14% QoQ
The EPS has grown by 32% YoY and by 7% from the previous quarter
Intellia Therapeutics's revenue has increased by 45% YoY but it has decreased by 2.3% QoQ
The gross profit has grown by 45% YoY but it has contracted by 2.3% from the previous quarter
Intellia Therapeutics's equity has decreased by 20% YoY and by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intelliatx.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NTLA

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
13.67%
1 week
8.19%
1 month
6.71%
1 year
92.96%
YTD
64.63%
QTD
15.44%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$66.09M
Gross profit
$66.09M
Operating income
-$420.72M
Net income
-$394.6M
Gross margin
100%
Net margin
-597%
The company's net margin rose by 48% YoY and by 2.1% QoQ
Intellia Therapeutics's operating margin has increased by 46% YoY and by 2.3% QoQ
Intellia Therapeutics's revenue has increased by 45% YoY but it has decreased by 2.3% QoQ
The gross profit has grown by 45% YoY but it has contracted by 2.3% from the previous quarter

Price vs fundamentals

How does NTLA's price correlate with its fundamentals

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
2.82
P/S
26.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
30.47
The EPS has grown by 32% YoY and by 7% from the previous quarter
The stock's P/B is 42% below its 5-year quarterly average of 4.3 but 24% above its last 4 quarters average of 2.0
Intellia Therapeutics's equity has decreased by 20% YoY and by 8% from the previous quarter
The price to sales (P/S) is 74% lower than the 5-year quarterly average of 88.9 but 5% higher than the last 4 quarters average of 22.2
Intellia Therapeutics's revenue has increased by 45% YoY but it has decreased by 2.3% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has grown by 48% YoY and by 2.1% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 10% YoY and by 3.9% from the previous quarter
Intellia Therapeutics's ROE has increased by 2.4% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has decreased by 33% YoY and by 19% QoQ
NTLA's current ratio is up by 24% year-on-year and by 20% since the previous quarter
The company's debt is 87% lower than its equity
The company's debt fell by 33% YoY and by 14% QoQ
Intellia Therapeutics's equity has decreased by 20% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.